Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
NCT01422213, Phase 3, Completed, H. Lundbeck A/S; results first posted 2014-08-05
Trial 12
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder | ClinicalTrials.gov |
| NCT number | NCT01422213 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 598 participants, actual | ClinicalTrials.gov |
| Lead sponsor | H. Lundbeck A/S | ClinicalTrials.gov |
| Conditions | Major Depressive Disorder | ClinicalTrials.gov |
| Interventions | Placebo, Vortioxetine (Lu AA21004), Vortioxetine (Lu AA21004) | ClinicalTrials.gov |
| First posted | 2011-08-23 | ClinicalTrials.gov |
| Last updated | 2014-08-05 | ClinicalTrials.gov |
| Other registries' IDs | eudract:2011-001572-19 | ClinicalTrials.gov |
| Results first posted | 2014-08-05 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | Baseline and Week 8 | DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning). RAVLT assesses verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. The scores are standardized by subtracting the overall mean change from baseline from the individual change from baseline and dividing by the standard deviation estimate of the change from baseline. The 2 tests, DSST and RAVLT are each assigned a weight of 0.5, the 2 subtests of RAVLT are each assigned a weight of 0.25. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | Baseline and Week 8 | Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in RAVLT (Acquisition) | Baseline and Week 8 | Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in RAVLT (Delayed Recall) | Baseline and Week 8 | Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in the TMT A (Speed of Processing) | Baseline and Week 8 | Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in the TMT B (Executive Function) | Baseline and Week 8 | TMT is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part B examines executive functioning and ability to shift cognitive set. The lower the score the faster the ability to shift cognitive set. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function) | Baseline and Week 8 | Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function) | Baseline and Week 8 | ClinicalTrials.gov | |
| Secondary | Change From Baseline to Week 8 in the SRT (Speed of Processing) | Baseline and Week 8 | Simple Reaction Time (SRT) is designed to assess psychomotor speed, and Choice Reaction Time (CRT) is designed to assess visual attention. Two computerised tests, part of the CogState battery were used to measure SRT and CRT in milliseconds: * The "detection task" measures SRT: the patient presses a "yes" button, whenever an onscreen playing card is turned over. * The "identification task" measures CRT: the patient presses a "yes" button whenever an onscreen playing card is turned over and is red, or a "no" button if the card is not red. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in the CRT (Attention) | Baseline and Week 8 | ClinicalTrials.gov | |
| Secondary | Change From Baseline to Week 8 in MADRS Total Score | Baseline and Week 8 | The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 in CGI-S Score | Baseline and Week 8 | The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. | ClinicalTrials.gov |
| Secondary | Clinical Status Using CGI-I Score at Week 8 | Week 8 | The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. | ClinicalTrials.gov |
| Secondary | Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline | Baseline and Week 8 | ClinicalTrials.gov | |
| Secondary | Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10) | Week 8 | ClinicalTrials.gov | |
| Secondary | Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score | Baseline and Week 1 | Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. In the week 1 analysis the vortioxetine 10 and 20 mg groups were pooled because patients randomized to vortioxetine 20 mg received vortioxetine 10 mg in the first week of the study. | ClinicalTrials.gov |
| Secondary | Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score | Baseline and Week 8 | Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. | ClinicalTrials.gov |
| Secondary | Risk of Suicidality Using C-SSRS Scores | Up to 8 weeks | The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. For 2 patients in each treament group (6 in total) the CSSRS assessments are missing during study. | ClinicalTrials.gov |
Outcomes 18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | Baseline and Week 8 | FAS | z score | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | Baseline and Week 8 | FAS | number of correct symbols | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in RAVLT (Acquisition) | Baseline and Week 8 | FAS | number of words correctly recalled | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in RAVLT (Delayed Recall) | Baseline and Week 8 | FAS | number of words correctly recalled | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in the TMT A (Speed of Processing) | Baseline and Week 8 | FAS | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in the TMT B (Executive Function) | Baseline and Week 8 | FAS | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function) | Baseline and Week 8 | FAS | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function) | Baseline and Week 8 | FAS | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in the SRT (Speed of Processing) | Baseline and Week 8 | FAS | log10 (ms) | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in the CRT (Attention) | Baseline and Week 8 | FAS | log10 (ms) | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in MADRS Total Score | Baseline and Week 8 | FAS | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 in CGI-S Score | Baseline and Week 8 | FAS | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Clinical Status Using CGI-I Score at Week 8 | Week 8 | FAS | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline | Baseline and Week 8 | FAS, last observation carried forward (LOCF) | percentage of participants | NUMBER | ClinicalTrials.gov |
| SECONDARY | Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10) | Week 8 | FAS, LOCF | percentage of participants | NUMBER | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score | Baseline and Week 1 | FAS, LOCF | z score | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score | Baseline and Week 8 | FAS, LOCF | z score | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Risk of Suicidality Using C-SSRS Scores | Up to 8 weeks | APTS | participants | NUMBER | ClinicalTrials.gov |
Results by group 59
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | Placebo | -0.235 | Standard Error 0.053 | z score | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | Vortioxetine 10 mg | 0.128 | Standard Error 0.052 | z score | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | Vortioxetine 20 mg | 0.095 | Standard Error 0.051 | z score | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | Placebo | 4.83 | Standard Error 0.63 | number of correct symbols | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | Vortioxetine 10 mg | 9.03 | Standard Error 0.63 | number of correct symbols | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | Vortioxetine 20 mg | 9.09 | Standard Error 0.61 | number of correct symbols | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Acquisition) | Placebo | 3.06 | Standard Error 0.34 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Acquisition) | Vortioxetine 10 mg | 4.08 | Standard Error 0.34 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Acquisition) | Vortioxetine 20 mg | 3.65 | Standard Error 0.33 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Delayed Recall) | Placebo | 0.91 | Standard Error 0.18 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Delayed Recall) | Vortioxetine 10 mg | 1.63 | Standard Error 0.18 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in RAVLT (Delayed Recall) | Vortioxetine 20 mg | 1.56 | Standard Error 0.17 | number of words correctly recalled | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT A (Speed of Processing) | Placebo | -7.07 | Standard Error 1.00 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT A (Speed of Processing) | Vortioxetine 10 mg | -10.84 | Standard Error 1.00 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT A (Speed of Processing) | Vortioxetine 20 mg | -10.87 | Standard Error 0.97 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT B (Executive Function) | Placebo | -13.84 | Standard Error 2.00 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT B (Executive Function) | Vortioxetine 10 mg | -21.41 | Standard Error 2.00 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in the TMT B (Executive Function) | Vortioxetine 20 mg | -22.85 | Standard Error 1.95 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function) | Placebo | -5.97 | Standard Error 0.93 | seconds | ClinicalTrials.gov | |
| Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function) | Vortioxetine 10 mg | -9.97 | Standard Error 0.93 | seconds | ClinicalTrials.gov |
Participant flow 9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 196 | ClinicalTrials.gov | |
| Overall Study | STARTED | Vortioxetine 10 mg | 195 | ClinicalTrials.gov | |
| Overall Study | STARTED | Vortioxetine 20 mg | 207 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Placebo | 163 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Vortioxetine 10 mg | 173 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Vortioxetine 20 mg | 178 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Placebo | 33 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Vortioxetine 10 mg | 22 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Vortioxetine 20 mg | 29 | ClinicalTrials.gov |
Adverse events 21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Placebo | 8 | 196 | ClinicalTrials.gov | |
| other | Nausea | Gastrointestinal disorders | Vortioxetine 10 mg | 32 | 195 | ClinicalTrials.gov | |
| other | Nausea | Gastrointestinal disorders | Vortioxetine 20 mg | 43 | 207 | ClinicalTrials.gov | |
| other | Nasopharyngitis | Infections and infestations | Placebo | 10 | 196 | ClinicalTrials.gov | |
| other | Nasopharyngitis | Infections and infestations | Vortioxetine 10 mg | 7 | 195 | ClinicalTrials.gov | |
| other | Nasopharyngitis | Infections and infestations | Vortioxetine 20 mg | 9 | 207 | ClinicalTrials.gov | |
| other | Headache | Nervous system disorders | Placebo | 14 | 196 | ClinicalTrials.gov | |
| other | Headache | Nervous system disorders | Vortioxetine 10 mg | 16 | 195 | ClinicalTrials.gov | |
| other | Headache | Nervous system disorders | Vortioxetine 20 mg | 26 | 207 | ClinicalTrials.gov | |
| serious | Hiatus hernia | Gastrointestinal disorders | Placebo | 1 | 196 | ClinicalTrials.gov | |
| serious | Hiatus hernia | Gastrointestinal disorders | Vortioxetine 10 mg | 0 | 195 | ClinicalTrials.gov | |
| serious | Hiatus hernia | Gastrointestinal disorders | Vortioxetine 20 mg | 0 | 207 | ClinicalTrials.gov | |
| serious | Cholecystitis | Hepatobiliary disorders | Placebo | 1 | 196 | ClinicalTrials.gov | |
| serious | Cholecystitis | Hepatobiliary disorders | Vortioxetine 10 mg | 0 | 195 | ClinicalTrials.gov | |
| serious | Cholecystitis | Hepatobiliary disorders | Vortioxetine 20 mg | 0 | 207 | ClinicalTrials.gov | |
| serious | Type 1 diabetes mellitus | Metabolism and nutrition disorders | Placebo | 0 | 196 | ClinicalTrials.gov | |
| serious | Type 1 diabetes mellitus | Metabolism and nutrition disorders | Vortioxetine 10 mg | 0 | 195 | ClinicalTrials.gov | |
| serious | Type 1 diabetes mellitus | Metabolism and nutrition disorders | Vortioxetine 20 mg | 1 | 207 | ClinicalTrials.gov | |
| serious | Hypertension | Vascular disorders | Placebo | 0 | 196 | ClinicalTrials.gov | |
| serious | Hypertension | Vascular disorders | Vortioxetine 10 mg | 0 | 195 | ClinicalTrials.gov |
Adverse event totals 9
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Placebo | ClinicalTrials.gov | ||
| Total, all-cause mortality | Vortioxetine 10 mg | ClinicalTrials.gov | ||
| Total, all-cause mortality | Vortioxetine 20 mg | ClinicalTrials.gov | ||
| Total, other adverse events | Placebo | 31 | 196 | ClinicalTrials.gov |
| Total, other adverse events | Vortioxetine 10 mg | 48 | 195 | ClinicalTrials.gov |
| Total, other adverse events | Vortioxetine 20 mg | 66 | 207 | ClinicalTrials.gov |
| Total, serious adverse events | Placebo | 2 | 196 | ClinicalTrials.gov |
| Total, serious adverse events | Vortioxetine 10 mg | 0 | 195 | ClinicalTrials.gov |
| Total, serious adverse events | Vortioxetine 20 mg | 2 | 207 | ClinicalTrials.gov |
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Choice Reaction Time | Secondary outcome | ConductCognition |
| Simple Reaction Time | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)